The first place in the nomination «Medicine of choice for the treatment and prevention of SARS and influenza among children» was granted to «Polyoxidonium», produced by NGO Petrovax Pharm.
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
The event took place within the framework of the educational project «We and Media». Participants of the round table discussed ways of fighting dangerous infectious diseases and the role of the media in the popularization of the vaccine prophylaxis.
Andrey Bougrov, Senior Vice President of MMC Norilsk Nickel and board member of the RSPP, chaired a joint meeting of the RSPP’s Committee on Corporate Relations and the National Council on Corporate Governance (NSKU) Working Group on Improving Corporate Law. Participants discussed the draft bill «On Amendments to the Federal Law ‘On Countering the Illegal Use of Insider Information and Market Manipulation and on Amending Certain Legislative Acts of the Russian Federation’.»
At the sixth annual Russian Pharma Awards 2017, Polyoxidonium, a Russian combination product that is an immunomodulator, detoxifier, and antioxidant, took the prize for «Product of choice for treating and preventing acute viral respiratory infection in children».